Strategic partnerships Invetx has recent and ongoing strategic collaborations with Absci and Nona Biosciences to develop next-generation animal health biotherapeutics using AI and Harbour Mice platforms, signaling a readiness to leverage external tech and partnerships to accelerate drug discovery sales opportunities.

Acquisition-backed growth As a Dechra division with a history of acquisition, Invetx benefits from integration potential, broader distribution, and increased credibility in animal health biotech, presenting a selling point for both collaboration and licensing deals with larger veterinary pharma players.

Robust IP platform The company centers on protein-based therapeutics with proprietary half-life extension technology and monoclonal antibody programs, offering recurring revenue potential through partnerships that license novel biologics and platform-enabled discoveries.

Revenue and funding With reported revenue in the lower to mid millions and substantial funding, Invetx demonstrates financial momentum and investment readiness for co-development, milestone-based deals, and scale-up collaborations with biotech and pharma clients.

Animal health focus Specialization in dogs and cats and broader animal health indications positions Invetx to pursue high-value collaborations with veterinary companies seeking innovative biologics, enabling targeted outreach to potential clients in pet care and livestock health segments.